Overview

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2032-06-30

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.

Phase:

PHASE2

Details

Lead Sponsor:

CSPC Megalith Biopharmaceutical Co.,Ltd.

Treatments:

Carboplatin
Cisplatin
osimertinib
Pemetrexed